US and EU Approve AstraZeneca’s Klygefa for Myasthenia Gravis
Key Facts
AstraZeneca announced on November 16, 2026, that Klygefa, whose generic name is gefurulimab, had received US Food and Drug Administration approval to treat adults with generalized myasthenia gravis who are positive for acetylcholine receptor antibodies. The company announced EU approval for the same patient group on the same day, as an add-on to standard therapy. The two approvals make the treatment available to specific patients based on their antibody status, not to everyone with myasthenia gravis. The US approval was based on results from the Phase III PREVAIL trial, which met its primary endpoint at week 26. AstraZeneca said the treatment showed clinical improvement as early as week one, sustained through one year in trial data.
On the primary MG-ADL measure, which tracks the disease’s impact on daily activities, the score improved by an average of 4.2 points among patients receiving gefurulimab at week 26, compared with 2.6 points with placebo. The treatment difference was 1.6 points in favor of the drug, with a 95% confidence interval of 0.8 to 2.4 points and a statistical value below 0.001, according to the study published in JAMA Neurology. The company reports the result as a difference of -1.6 points, with a confidence interval from -2.4 to -0.8 and a p-value of <0.0001. The secondary clinical QMG measure also improved by an average of 4.5 points with treatment, compared with 2.4 points with placebo. The treatment difference in QMG was 2 points in favor of gefurulimab, with a 95% confidence interval of 1.1 to 3.1 points and a statistical value below 0.001.
PREVAIL enrolled 260 patients in 20 countries and was designed as a randomized, double-blind, placebo-controlled Phase III trial. According to the study published in JAMA Neurology, the trial was conducted at 113 sites, and participant screening and randomization ran from November 2022 to November 2024. AstraZeneca had announced on July 24, 2025, that gefurulimab met its primary endpoint and all secondary endpoints. The company said at the time that the data would be presented at a medical meeting and shared with global regulatory authorities. The week 26 measurement results form the core of the clinical evidence underpinning US approval.
Klygefa is administered as a once-weekly subcutaneous injection using an autoinjector and is a dual-binding nanobody inhibitor of complement C5. AstraZeneca says the dosing regimen combines C5 inhibition with weekly self-injection. The dosing frequency differs from other options cited in the study: eculizumab is administered intravenously every two weeks, ravulizumab every eight weeks, while zilucoplan is injected subcutaneously once daily. This difference stands out in the dosing schedule as one feature of the approved treatment. Under the EU approval, Klygefa remains an add-on to standard therapy for the specified patient group.
The FDA label includes a warning of an increased risk of serious meningococcal infections with Klygefa. The label recommends completing or updating meningococcal vaccination at least two weeks before the first dose. The recommendation covers serogroups A, C, W, Y and B. The label permits treatment to begin before that period has elapsed if the risks of delaying it outweigh the risks. The most common adverse reactions reported by the company among patients receiving the drug were injection-site reactions at 12%, back pain at 8% and vomiting at 5%. The company said most reported adverse reactions were mild to moderate.
AstraZeneca estimated that 98,500 people in the United States have generalized myasthenia gravis, including 81,000 who are positive for acetylcholine receptor antibodies. The second figure represents the group targeted by the two announced approvals, while the first reflects the company’s estimate of the total number of people with the disease in the United States. On regulatory expansion, the company said applications based on PREVAIL results remain under review in China and other countries. AstraZeneca shares (AZN) closed at $184.45 on November 13, 2026, after three consecutive closes below the November 9 close of $189.39. The stock recorded $186.76 on November 10, $185.48 on November 11 and $184.38 on November 12; available EL7 data do not include the stock’s movement during the session in which the approvals were announced.